This research will establish and continuously improve the FAD research network in conjunction with multi-center institutions nationwide. By collecting information on the family's demography, genetics, neuropsychology, neuroimaging, biomarkers and other information, we can understand the current FAD population in China, clarify the genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of AD in China; which will lay the foundation for ameliorating clinical diagnosis and treatment, establishing a Chinese FAD clinical database and an international cooperative research platform. 1. To set up a multi-center, nationwide FAD research network and database platform in China 2. To clarify the epidemiological characteristics of FAD in China. 3. To clarify the genetic characteristics of FAD in China. 4. To clarify the clinical characteristics and disease development laws of FAD. 5. To discover and verify the early diagnosis biomarkers of AD. 6. To establish a genetic counseling model.
1. The network and database include ADAD cohort of the known mutations of PSEN1, PSEN2 and APP (mutation carriers and noncarriers; pre-symptomatic and symptomatic) and unknown mutations cohort. 2. Conduct a comprehensive FAD epidemiological survey in China to clarify the impact of different nationalities, regions, gender, age, living environment (rural/urban), education level, etc. on the occurrence and development of the disease. 3. This project is to discover new FAD mutation sites,pathogenic genes, to protective genes, to explore the pathogenic and protective mechanism, to analyze the disease development laws of families with different sizes of FAD in China, and to clarify the frequency distribution of mutant genes in the Chinese FAD population. 4. The project will collect and regularly follow-up the samples (blood, urine and saliva etc.) and data (neuropsychology, imaging etc.) in the cohort. Emphasis is placed on the occurrence and development of asymptomatic mutant gene carriers from asymptomatic to symptomatic periods. 5. In the FAD family cohort, we will screen high-sensitivity and high-specificity body fluid markers suitable for Chinese people, verify in the SAD cohort, and establish a prediction model of body fluid markers for AD occurrence and disease progression; use structural MRI, dual tracer 18F-FDG PET and 11C-PIB PET multimodal imaging technology, dynamically monitor the dynamic evolution of imaging biomarkers such as brain structure, glucose metabolism and Aβ deposition at various stages of AD progression. 6. We will combine with the genetic characteristics of Chinese FAD to analyze the impact of lifestyle, physical exercise, nootropic drugs, cognitive training, etc. on the disease progression of FAD patients or asymptomatic mutant gene carriers, to establish a genetic counseling model.
Study Type
OBSERVATIONAL
Enrollment
40,000
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
RECRUITINGBeijing Geriatric Hospital
Changping, Beijing Municipality, China
RECRUITINGBeijing Chao Yang Hospital
Chaoyang, Beijing Municipality, China
RECRUITINGChina-Japan Friendship Hospital
Chaoyang, Beijing Municipality, China
The prevalence of gene mutations in familial Alzheimer's disease in China.
Gene analysis of known mutations (PSEN1, PSEN2 and APP), apolipoprotein E (APOE) genotype and unknown mutations in familial Alzheimer's disease patients.
Time frame: An Average of 1 year
The development patterns of genetic, biofluid, imaging, and neuropsychological markers of FAD.
The development patterns of genetic, biofluid, imaging, and neuropsychological markers of FAD. The dynamic changes of biochemical, pathological, structural and functional markers with disease progression.
Time frame: An Average of 3 to 10 years
Changes of neuropsychological function in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.
Changes of neuropsychological function measured by neuropsychological assessment battery.
Time frame: An Average of 1 year
Changes of brain structure in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.
Changes of structure of the whole brain, hippocampus other brain structures measured by MRI.
Time frame: An Average of 1 year
Changes of brain glucose metabolism in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.
Changes of glucose metabolism of the whole brain, hippocampus and other brain structures as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET).
Time frame: An Average of 1 year
Changes of brain amyloid deposition in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.
Changes of amyloid deposition of the whole brain, hippocampus and other brain structures as measured by amyloid PET.
Time frame: An Average of 1 year
Changes of brain tau deposition in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.
Changes of tau deposition of the whole brain, hippocampus and other brain structures as measured by tau PET.
Time frame: An Average of 1 year
Changes of humoral biomarkers in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.
Humoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine.
Time frame: Each biomarker with time frame of average 1 year
The effective non-pharmacologic treatment(NPT) intervention
The effective non-pharmacologic treatment(NPT) intervention- including lifestyle(diet and sleep habits, smoking, drinking and social networking), health products, exercise habits, cognitive training, risk factor control- on APOE ε4 carriers, MCI and dementia patients using questionnaire.
Time frame: An Average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dongfang Hospital Affiliated to Beijing University of Chinese Medicine
Fengtai, Beijing Municipality, China
RECRUITINGChinese PLA General Hospital
Haidian, Beijing Municipality, China
RECRUITINGFu Xing Hospital, Capital Medical University
Haidian, Beijing Municipality, China
RECRUITINGPeking University Third Hospital
Haidian, Beijing Municipality, China
RECRUITINGPeking Union Medical College Hospital
Xicheng, Beijing Municipality, China
RECRUITINGPeking University First Hospital
Xicheng, Beijing Municipality, China
RECRUITING...and 55 more locations